DanielPeterPetrylakMD

Oncology • New Haven, CT

Genitourinary Oncology, Hematologic Oncology

Yale University Cancer Center

Join to view full profile

Dr. Petrylak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Petrylak's full profile

Already have an account?

Office
35 Park Street, NP-4
New Haven, CT
New Haven, CT 06510
Phone+1 203-200-4822
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1985 - 1988
Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1985 - 2026
CT State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2006-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2005-2009, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 3
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1998 Feb 01
Unknown status
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Start of enrollment: 1998 Aug 01
Unknown status
Phase 1
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Oct 01
Completed
Phase 3
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Start of enrollment: 2001 Feb 01
Completed
Phase 2
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) Start of enrollment: 2018 Oct 12
Completed
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg, J., Mamtani, R., Sonpavde, G., Loriot, Y., Duran, I., Lee, J., Matsubara, N., Vulsteke, C., Castellano, D., Sridhar, S., Pappot, H., Gurney, H., Bedke, J., ...> ;European Urology. 2024 Feb 27
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 C...
Petros Grivas, Damien Pouessel, Chandler H Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Fléchon, Chethan Ramamu...> ;Journal of Clinical Oncology. 2024 Apr 20
2 citations
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pem...
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, Daniel P Petrylak, Thomas W Flaig, Helen H Moon, Terence W Friedlander, Nataliya Mar, Rana R McKay, Sandy ...> ;Journal of Clinical Oncology. 2024 Apr 20
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Petrylak, D., Eigl, B., George, S., Heath, E., Hotte, S., Chism, D., Nabell, L., Picus, J., Cheng, S., Appleman, L., Sonpavde, G., Morgans, A., Pourhosseini, P., Wu, R...> ;Clinical Cancer Research. 2024 Jan 5
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.
Santasusagna, S., Zhu, S., Jawalagatti, V., Carceles-Cordon, M., Ertel, A., Garcia-Longarte, S., Song, W., Fujiwara, N., Li, P., Mendizabal, I., Petrylak, D., Kelly, W...> ;Cancer Discovery. 2023 Dec 12
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Future Oncology. 2024 Mar 1
1 citations
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Mainten...
Srikala S Sridhar, Thomas Powles, Miguel Á Climent Durán, Se Hoon Park, Francesco Massari, Antoine Thiery-Vuillemin, Begoña P Valderrama, Anders Ullén, Norihiko Tsuchi...> ;European Urology. 2024 Feb 1
1 citations
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
Zechen Wang, Viswanathan Muthusamy, Daniel P Petrylak, Karen S Anderson> ;NPJ Precision Oncology. 2023 Jul 21
16 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.
Grace Sun, Don S Dizon, Connie M Szczepanek, Daniel P Petrylak, Dana B Sparks, Catherine Tangen, Primo Lucky N Lara Jr, Ian M Thompson Jr, Charles David Blanke> ;JCO Oncology Practice. 2023 Aug 1
2 citations
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Andrew J Armstrong, Taro Iguchi, Arun A Azad, Arnauld Villers, Boris Alekseev, Daniel P Petrylak, Russell Z Szmulewitz, Antonio Alcaraz, Neal D Shore, Jeffrey Holzbeie...> ;European Urology. 2023 Aug 1
13 citations
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Petros Grivas, Se Hoon Park, Eric Voog, Claudia Caserta, Howard Gurney, Joaquim Bellmunt, Haralabos Kalofonos, Anders Ullén, Yohann Loriot, Srikala S Sridhar, Yoshiaki...> ;European Urology. 2023 Jul 1
7 citations
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Yi-Tsung Lu, Melissa Plets, Gareth Morrison, Alexander T Cunha, Steven Y Cen, Suhn K Rhie, Kimberly D Siegmund, Siamak Daneshmand, David I Quinn, Joshua J Meeks, Seth ...> ;European Urology Oncology. 2023 Oct 1
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, Lawrence I Karsh, David I Quinn, Jason M Hafron, Helen M Wilfehrt, Matthew Harmon, Nadeem A Sheikh, N...> ;Clinical Cancer Research. 2023 Jul 5
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C Araujo, Christopher Logothetis, Cora N Sternberg, Andrew J Armstrong, Michael A Carducci, Kim N Chi, Johann S de Bo...> ;Journal of Clinical Oncology. 2023 May 20
3 citations
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic c...
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
20 citations
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky, Y Fradet, J-L Lee, L Fong, N J Vogelzang, M A Climent, A Necchi, D P Petrylak, E R Plimack, J Z Xu, ...> ;Annals of Oncology. 2023 Mar 1
1 citations
Effect of Androgen-Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients.
Serhan Ünlü, Junghee Jenny Shin, Jennefer Par-Young, Michael Simonov, Joseph Vinetz, Daniel P Petrylak, Insoo Kang, Joseph W Kim> ;Cancer Investigation. 2023 Jan 1
14 citations
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W Kim, Rana R McKay, Marc R Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B Davis, Paul Monk, Leonard J Appleman, Primo N Lara Jr, Ulka N Vaishampayan, Jingsong ...> ;Journal of Clinical Oncology. 2023 Feb 1
27 citations
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on/mRNA Expression.
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S van der Heijden, Eli Rosenbaum, Nicola...> ;Journal of Clinical Oncology. 2023 Jan 20
7 citations
Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated lo...
Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E Rosenberg, Daniel P Petrylak, Maria Matsangou, Chunzhang...> ;Cancer Medicine. 2023 Feb 1
66 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Journal of Clinical Oncology. 2023 Jan 1
13 citations
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Karim Fizazi, Margitta Retz, Daniel P Petrylak, Jeffrey C Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravi...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
2 citations
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Ronald de Wit, Thomas Powles, Daniel Castellano, Andrea Necchi, Jae-Lyun Lee, Michiel S van der Heijden, Nobuaki Matsubara, Aristotelis Bamias, Aude Fléchon, Cora N St...> ;British Journal of Clinical Pharmacology. 2022 Jul 1
1 citations
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore, Fr...> ;The Prostate. 2022 Sep 1
Join now to see all

Journal Articles

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Lectures

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
6th Annual Interdisciplinary Prostate Cancer Congress®
Physicians' Education Resource, LLC , Physicians' Education Resource, LLC, New York, New York - 3/16/2013